Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Krishnan Ramaswamy

10PUBLICATIONS
15CO-AUTHORS
Molecular targetsPredictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

Sort by Publication Date:
|Jul 24, 2025
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.

Stephen J Freedland, Agnes Hong, Nader El-Chaar

|Sep 13, 2024
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment.

Stephen J Freedland, Wei Gao, Angela Lax

|Apr 02, 2024
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.

Daniel J George, Neeraj Agarwal, Krishnan Ramaswamy

|Mar 28, 2024
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.

Daniel J George, Krishnan Ramaswamy, Hongbo Yang

|Dec 14, 2022
Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.

Stephen J Freedland, Agnes Hong, Nader El-Chaar

|Jul 15, 2022
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.

Scott T Tagawa, Krishnan Ramaswamy, Ahong Huang

Pageof 2

Frequent Collaborators

5 joint publications

Stephen J Freedland

3 joint publications

Scott T Tagawa

3 joint publications

Daniel J George

2 joint publications

Jasmina Ivanova

1 joint publications

Andrew J Armstrong

1 joint publications

Tomasz M Beer

1 joint publications

Maha Hussain

1 joint publications

Fred Saad

1 joint publications

Jack Mardekian

1 joint publications

Alicia K Morgans

Frequent Collaborators

5 joint publications

Stephen J Freedland

3 joint publications

Scott T Tagawa

3 joint publications

Daniel J George

2 joint publications

Jasmina Ivanova

Top Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on : Mar 06, 2018

13.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on : May 19, 2022

7.6K
See more related videos

Top Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on : Mar 06, 2018

13.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on : May 19, 2022

7.6K
See more related videos